Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 14:12:113.
doi: 10.3389/fnana.2018.00113. eCollection 2018.

Advances in Parkinson's Disease: 200 Years Later

Affiliations
Review

Advances in Parkinson's Disease: 200 Years Later

Natalia López-González Del Rey et al. Front Neuroanat. .

Abstract

When James Parkinson described the classical symptoms of the disease he could hardly foresee the evolution of our understanding over the next two hundred years. Nowadays, Parkinson's disease is considered a complex multifactorial disease in which genetic factors, either causative or susceptibility variants, unknown environmental cues, and the potential interaction of both could ultimately trigger the pathology. Noteworthy advances have been made in different fields from the clinical phenotype to the decoding of some potential neuropathological features, among which are the fields of genetics, drug discovery or biomaterials for drug delivery, which, though recent in origin, have evolved swiftly to become the basis of research into the disease today. In this review, we highlight some of the key advances in the field over the past two centuries and discuss the current challenges focusing on exciting new research developments likely to come in the next few years. Also, the importance of pre-motor symptoms and early diagnosis in the search for more effective therapeutic options is discussed.

Keywords: Parkinson’s disease; drug delivery systems; focused ultrasound; genetics; non-motor symptoms.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Breakthroughs in Parkinson’s disease history.
FIGURE 2
FIGURE 2
Drug delivery systems under investigation for Parkinson’s disease treatment.

References

    1. Adil M. M., Vazin T., Ananthanarayanan B., Rodrigues G. M. C., Rao A. T., Kulkarni R. U., et al. (2017). Engineered hydrogels increase the post-transplantation survival of encapsulated hESC-derived midbrain dopaminergic neurons. Biomaterials 136 1–11. 10.1016/j.biomaterials.2017.05.008 - DOI - PubMed
    1. Anden N. E., Dahlstroem A., Fuxe K., Larsson K. (1965). Further evidence for the presence of nigro-neostriatal dopamine neurons in the rat. Am. J. Anat. 116 329–333. 10.1002/aja.1001160117 - DOI - PubMed
    1. Antonini A., Moro E., Godeiro C., Reichmann H. (2018). Medical and surgical management of advanced Parkinson’s disease. Mov. Disord. 33 1–9. 10.1002/mds.27340 - DOI - PubMed
    1. Barker R. A., Drouin-Ouellet J., Parmar M. (2015). Cell-based therapies for Parkinson disease—past insights and future potential. Nat. Rev. Neurol. 11 492–503. 10.1038/nrneurol.2015.123 - DOI - PubMed
    1. Bergman H., Wichmann T., DeLong M. R. (1990). Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 1436–1438. 10.1126/science.2402638 - DOI - PubMed